Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Checkpoint Therapeutics Inc. defeated investor claims it concealed the likelihood US regulators would deny its skin cancer ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Macquarie has reaffirmed its ‘outperform’ rating on Sun Pharmaceutical Industries Ltd. and raised its target price to Rs ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. My name is Rochelle, and I will be your ...

Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoin ...

Detailed price information for Checkpoint Therapeutics Inc (CKPT-Q) from The Globe and Mail including charting and trades.

BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...